Expression of somatostatin and somatostatin receptor subtypes in Apolipoprotein D (ApoD) knockout mouse brain: An immunohistochemical analysis

Journal of Chemical Neuroanatomy

Volumn 38, Issue 1, 2009, Pages 20-33

  Rajput, Padmesh S ^a   Billova, Sabina ^a   Patel, Shutish C ^b   Kharmate, Geetanjali ^a   Somvanshi, Rishi K ^a   Kumar, Ujendra ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b New England Biomedical Research Center   (United States)

Author keywords

ApoD; Degeneration; Immunohistochemistry; Neuropeptide; Somatostatin; Somatostatin receptors

Indexed keywords

APOLIPOPROTEIN D; PROTEIN ANTIBODY; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN TISSUE; CELL MEMBRANE; CONTROLLED STUDY; CORPUS STRIATUM; CYTOPLASM; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KNOCKOUT MOUSE; MALE; MOUSE; NERVE PROJECTION; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STRAIN DIFFERENCE; SUBSTANTIA NIGRA; TISSUE DISTRIBUTION; WILD TYPE;

AMYGDALA; ANIMALS; APOLIPOPROTEINS D; BRAIN; BRAIN CHEMISTRY; BRAIN MAPPING; CELL MEMBRANE; CEREBRAL CORTEX; CORPUS STRIATUM; CYTOPLASM; DOWN-REGULATION; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; NEURONS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; SUBSTANTIA NIGRA;

EID: 67549134205     PISSN: 08910618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchemneu.2009.05.004     Document Type: Article

References (95)

1. Agren H., and Lundqvist G. Low levels of somatostatin in human CSF mark depressive episodes. Psychoneuroendocrinology 9 (1984) 233-248
2. Navarro A.A., Del Valle E., del Rey C.G., and Tolivia J. Immunohistochemical presence of Apolipoprotien D in senile plaques. J. Histotechnol. 24 (2001) 45-48
3. Andersen J.K. Oxidative stress in neurodegeneration: cause or consequence?. Nat. Med. 10 Suppl. (2004) S18-S25
4. Arias-Diaz J., Vara E., Torres-Melero J., Garcia C., Hernandez J., and Balibrea J.L. Local production of oxygen free radicals and nitric oxide in rat diaphragm during sepsis: effects of pentoxifylline and somatostatin. Eur. J. Surg. 163 (1997) 619-625
5. Arvindakshan M., Sitasawad S., Debsikdar V., Ghate M., Evans D., Horrobin D.F., Bennett C., Ranjekar P.K., and Mahadik S.P. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol. Psychiatry 53 (2003) 56-64
6. Banki C.M., Karmacsi L., Bissette G., and Nemeroff C.B. CSF corticotropin releasing hormone, somatostatin, and thyrotropin releasing hormone in schizophrenia. Psychiatry Res. 43 (1992) 13-21
7. Baragli A., Alturaihi H., Watt H.L., Abdallah A., and Kumar U. Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell. Signal. 19 (2007) 2304-2316
8. Beal M.F., Mazurek M.F., Tran V.T., Chattha G., Bird E.D., and Martin J.B. Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease. Science 229 (1985) 289-291
9. Belloir B., Kovari E., Surini-Demiri M., and Savioz A. Altered apolipoprotein D expression in the brain of patients with Alzheimer disease. J. Neurosci. Res. 64 (2001) 61-69
10. Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Rivier J., and Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179 (1973) 77-79
11. Calabrese V., Lodi R., Tonon C., D'Agata V., Sapienza M., Scapagnini G., Mangiameli A., Pennisi G., Stella A.M., and Butterfield D.A. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J. Neurol. Sci. 233 (2005) 145-162
12. Calero M., Rostagno A., Matsubara E., Zlokovic B., Frangione B., and Ghiso J. Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc. Res. Tech. 50 (2000) 305-315
13. Cervia D., and Bagnoli P. An update on somatostatin receptor signaling in native systems and new insights on their pathophysiology. Pharmacol. Ther. 116 (2007) 322-341
14. Choi-Miura N.H., Ihara Y., Fukuchi K., Takeda M., Nakano Y., Tobe T., and Tomita M. SP-40,40 is a constituent of Alzheimer's amyloid. Acta Neuropathol. 83 (1992) 260-264
15. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., and Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993) 921-923
16. Dandoy-Dron F., Guillo F., Benboudjema L., Deslys J.P., Lasmezas C., Dormont D., Tovey M.G., and Dron M. Gene expression in scrapie. Cloning of a new scrapie-responsive gene and the identification of increased levels of seven other mRNA transcripts. J. Biol. Chem. 273 (1998) 7691-7697
17. Davies P., Katzman R., and Terry R.D. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementia. Nature 288 (1980) 279-280
18. DeMattos R.B., O'Dell M.A., Parsadanian M., Taylor J.W., Harmony J.A., Bales K.R., Paul S.M., Aronow B.J., and Holtzman D.M. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 10843-10848
19. Dilley W.G., Haagensen D.E., Cox C.E., and Wells Jr. S.A. Immunologic and steroid binding properties of the GCDFP-24 protein isolated from human breast gross cystic disease fluid. Breast Cancer Res. Treat. 16 (1990) 253-260
20. Dournaud P., Gu Y.Z., Schonbrunn A., Mazella J., Tannenbaum G.S., and Beaudet A. Localization of the somatostatin receptor SST2A in rat brain using a specific anti-peptide antibody. J. Neurosci. 16 (1996) 4468-4478
21. Epelbaum J., Tapia Arancibia L., Kordon C., and Enjalbert A. Characterization, regional distribution, and subcellular distribution of 125I-Tyr1-somatostatin binding sites in rat brain. J. Neurochem. 38 (1982) 1515-1523
22. Franz G., Reindl M., Patel S.C., Beer R., Unterrichter I., Berger T., Schmutzhard E., Poewe W., and Kampfl A. Increased expression of apolipoprotein D following experimental traumatic brain injury. J. Neurochem. 73 (1999) 1615-1625
23. Ganfornina M.D., Do Carmo S., Lora J.M., Torres-Schumann S., Vogel M., Allhorn M., Gonzalez C., Bastiani M.J., Rassart E., and Sanchez D. Apolipoprotein D is involved in the mechanisms regulating protection from oxidative stress. Aging Cell 7 (2008) 506-515
24. Gasparini L., Ongini E., and Wenk G. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. J. Neurochem. 91 (2004) 521-536
25. Geci C., How J., Alturaihi H., and Kumar U. Beta-amyloid increases somatostatin expression in cultured cortical neurons. J. Neurochem. 101 (2007) 664-673
26. 2-induced oxidative stress. J. Neurochem. 96 (2006) 77
27. Grant M., Patel R.C., and Kumar U. The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors. J. Biol. Chem. 279 (2004) 38636-38643
28. Grant M., Collier B., and Kumar U. Agonist-dependent dissociation of human somatostatin receptor 2 dimers: a role in receptor trafficking. J. Biol. Chem. 279 (2004) 36179-36183
29. Grant M., Alturaihi H., Jaquet P., Collier B., and Kumar U. Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol. Endocrinol. 22 (2008) 2278-2292
30. Grouselle D., Winsky-Sommerer R., David J.P., Delacourte A., Dournaud P., and Epelbaum J. Loss of somatostatin-like immunoreactivity in the frontal cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele. Neurosci. Lett. 255 (1998) 21-24
31. Handel M., Schulz S., Stanarius A., Schreff M., Erdtmann-Vourliotis M., Schmidt H., Wolf G., and Hollt V. Selective targeting of somatostatin receptor 3 to neuronal cilia. Neuroscience 89 (1999) 909-926
32. Helboe L., Stidsen C.E., and Moller M. Immunohistochemical and cytochemical localization of the somatostatin receptor subtype sst1 in the somatostatinergic parvocellular neuronal system of the rat hypothalamus. J. Neurosci. 18 (1998) 4938-4945
33. Helboe L., Hay-Schmidt A., Stidsen C.E., and Moller M. Immunohistochemical localization of the somatostatin receptor subtype 2 (sst2) in the central nervous system of the golden hamster (Mesocricetus auratus). J. Comp. Neurol. 405 (1999) 247-261
34. Helyes Z., Pinter E., Nemeth J., Sandor K., Elekes K., Szabo A., Pozsgai G., Keszthelyi D., Kereskai L., Engstrom M., Wurster S., and Szolcsanyi J. Effects of the somatostatin receptor subtype 4 selective agonist J-2156 on sensory neuropeptide release and inflammatory reactions in rodents. Br. J. Pharmacol. 149 (2006) 405-415
35. Hervieu G., and Emson P.C. The localization of somatostatin receptor 1 (sst1) immunoreactivity in the rat brain using an N-terminal specific antibody. Neuroscience 85 (1998) 1263-1284
36. Hildebrand M.S., de Silva M.G., Klockars T., Solares C.A., Hirose K., Smith J.D., Patel S.C., and Dahl H.H. Expression of the carrier protein apolipoprotein D in the mouse inner ear. Hear Res. 200 (2005) 102-114
37. Johansson O., Hokfelt T., and Elde R.P. Immunohistochemical distribution of somatostatin-like immunoreactivity in the central nervous system of the adult rat. Neuroscience 13 (1984) 265-339
38. Kalman J., McConathy W., Araoz C., Kasa P., and Lacko A.G. Apolipoprotein D in the aging brain and in Alzheimer's dementia. Neurol. Res. 22 (2000) 330-336
39. Klein J.A., and Ackerman S.L. Oxidative stress, cell cycle, and neurodegeneration. J. Clin. Invest. 111 (2003) 785-793
40. Krantic S., Robitaille Y., and Quirion R. Deficits in the somatostatin SS1 receptor sub-type in frontal and temporal cortices in Alzheimer's disease. Brain Res. 573 (1992) 299-304
41. Krantic S., Martel J.C., Weissmann D., Pujol J.F., and Quirion R. Quantitative radioautographic study of somatostatin receptors heterogeneity in the rat extrahypothalamic brain. Neuroscience 39 (1990) 127-137
42. Kumar U. Characterization of striatal cultures with the effect of QUIN and NMDA. Neurosci. Res. 49 (2004) 29-38
43. Kumar U. Expression of somatostatin receptor subtypes (SSTR1-5) in Alzheimer's disease brain: an immunohistochemical analysis. Neuroscience 134 (2005) 525-538
44. Kumar U. Colocalization of somatostatin receptor subtypes (SSTR1-5) with somatostatin, NADPH-diaphorase (NADPH-d), and tyrosine hydroxylase in the rat hypothalamus. J. Comp. Neurol. 504 (2007) 185-205
45. Kumar U. Somatostatin in medium-sized aspiny interneurons of striatum is responsible for their preservation in quinolinic acid and N-methyl-d-asparate-induced neurotoxicity. J. Mol. Neurosci. 35 (2008) 345-354
46. Kumar U., Asotra K., Patel S.C., and Patel Y.C. Expression of NMDA receptor-1 (NR1) and Huntingtin in striatal neurons which colocalize somatostatin, neuropeptide Y, and NADPH diaphorase: a double-label histochemical and immunohistochemical study. Exp. Neurol. 145 (1997) 412-424
47. Kumar U., Laird D., Srikant C.B., Escher E., and Patel Y.C. Expression of the five somatostatin receptor (SSTR1-5) subtypes in rat pituitary somatotrophes: quantitative analysis by double-layer immunofluorescence confocal microscopy. Endocrinology 138 (1997) 4473-4476
48. Kumar U., Sasi R., Suresh S., Patel A., Thangaraju M., Metrakos P., Patel S.C., and Patel Y.C. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 48 (1999) 77-85
49. Lahlou H., Guillermet J., Hortala M., Vernejoul F., Pyronnet S., Bousquet C., and Susini C. Molecular signaling of somatostatin receptors. Ann. N. Y. Acad. Sci. 1014 (2004) 121-131
50. Lamberts S.W., van der Lely A.J., de Herder W.W., and Hofland L.J. Octreotide. N. Engl. J. Med. 334 (1996) 246-254
51. Leroux P., Quirion R., and Pelletier G. Localization and characterization of brain somatostatin receptors as studied with somatostatin-14 and somatostatin-28 receptor radioautography. Brain Res. 347 (1985) 74-84
52. Martin-Rehrmann M.D., Hoe H.S., Capuani E.M., and Rebeck G.W. Association of apolipoprotein J-positive beta-amyloid plaques with dystrophic neurites in Alzheimer's disease brain. Neurotox. Res. 7 (2005) 231-242
53. Martin J.L., Chesselet M.F., Raynor K., Gonzales C., and Reisine T. Differential distribution of somatostatin receptor subtypes in rat brain revealed by newly developed somatostatin analogs. Neuroscience 41 (1991) 581-593
54. Morais Cabral J.H., Atkins G.L., Sanchez L.M., Lopez-Boado Y.S., Lopez-Otin C., and Sawyer L. Arachidonic acid binds to apolipoprotein D: implications for the protein's function. FEBS Lett. 366 (1995) 53-56
55. Muffat J., Walker D.W., and Benzer S. Human ApoD, an apolipoprotein up-regulated in neurodegenerative diseases, extends lifespan and increases stress resistance in Drosophila. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 7088-7093
56. Namba Y., Tomonaga M., Kawasaki H., Otomo E., and Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541 (1991) 163-166
57. Ong W.Y., He Y., Suresh S., and Patel S.C. Differential expression of apolipoprotein D and apolipoprotein E in the kainic acid-lesioned rat hippocampus. Neuroscience 79 (1997) 359-367
58. Ordonez C., Navarro A., Perez C., Astudillo A., Martinez E., and Tolivia J. Apolipoprotein D expression in substantia nigra of Parkinson disease. Histol. Histopathol. 21 (2006) 361-366
59. Patel S.C., Alturaihi H., Smith J.D., Ong W.Y., and Kumar U. Dopamine receptor expression in ApoD-/-, NPC1-/- and ApoD-/-NPC1-/- mice. Program Annual Meeting Society for Neuroscience. New Orleans, Louisiana, USA (2003)
60. Patel S.C., Asotra K., Patel Y.C., McConathy W.J., Patel R.C., and Suresh S. Astrocytes synthesize and secrete the lipophilic ligand carrier apolipoprotein D. Neuroreport 6 (1995) 653-657
61. Patel Y.C. Molecular pharmacology of somatostatin receptor subtypes. J. Endocrinol. Invest. 20 (1997) 348-367
62. Patel Y.C., Panetta R., Escher E., Greenwood M., and Srikant C.B. Expression of multiple somatostatin receptor genes in AtT-20 cells. Evidence for a novel somatostatin-28 selective receptor subtype. J. Biol. Chem. 269 (1994) 1506-1509
63. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. 4th edition (1998), Academic Press, New York
64. Prasad K.N., Cole W.C., and Prasad K.C. Risk factors for Alzheimer's disease: role of multiple antioxidants, non-steroidal anti-inflammatory and cholinergic agents alone or in combination in prevention and treatment. J. Am. Coll. Nutr. 21 (2002) 506-522
65. Ramirez J.L., Mouchantaf R., Kumar U., Otero Corchon V., Rubinstein M., Low M.J., and Patel Y.C. Brain somatostatin receptors are up-regulated in somatostatin-deficient mice. Mol. Endocrinol. 16 (2002) 1951-1963
66. Ramirez J.L., Grant M., Norman M., Wang X.P., Moldovan S., de Mayo F.J., Brunicardi C., and Kumar U. Deficiency of somatostatin (SST) receptor type 5 (SSTR5) is associated with sexually dimorphic changes in the expression of SST and SST receptors in brain and pancreas. Mol. Cell. Endocrinol. 221 (2004) 105-119
67. Rassart E., Bedirian A., Do Carmo S., Guinard O., Sirois J., Terrisse L., and Milne R. Apolipoprotein D. Biochim. Biophys. Acta 1482 (2000) 185-198
68. Raynor K., and Reisine T. Analogs of somatostatin selectively label distinct subtypes of somatostatin receptors in rat brain. J. Pharmacol. Exp. Ther. 251 (1989) 510-517
69. Reubi J.C., and Maurer R. Autoradiographic mapping of somatostatin receptors in the rat central nervous system and pituitary. Neuroscience 15 (1985) 1183-1193
70. Rickhag M., Wieloch T., Gido G., Elmer E., Krogh M., Murray J., Lohr S., Bitter H., Chin D.J., von Schack D., Shamloo M., and Nikolich K. Comprehensive regional and temporal gene expression profiling of the rat brain during the first 24 h after experimental stroke identifies dynamic ischemia-induced gene expression patterns, and reveals a biphasic activation of genes in surviving tissue. J. Neurochem. 96 (2006) 14-29
71. Rocheville M., Lange D.C., Kumar U., Patel S.C., Patel R.C., and Patel Y.C. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288 (2000) 154-157
72. Saunders A.M., Strittmatter W.J., Schmechel D., George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crapper-MacLachlan D.R., Alberts M.J., et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43 (1993) 1467-1472
73. Schindler M., Humphrey P.P., and Emson P.C. Somatostatin receptors in the central nervous system. Prog. Neurobiol. 50 (1996) 9-47
74. Schindler M., Sellers L.A., Humphrey P.P., and Emson P.C. Immunohistochemical localization of the somatostatin SST2(A) receptor in the rat brain and spinal cord. Neuroscience 76 (1997) 225-240
75. Schindler M., Humphrey P.P., Lohrke S., and Friauf E. Immunohistochemical localization of the somatostatin sst2(b) receptor splice variant in the rat central nervous system. Neuroscience 90 (1999) 859-874
76. Schreff M., Schulz S., Handel M., Keilhoff G., Braun H., Pereira G., Klutzny M., Schmidt H., Wolf G., and Hollt V. Distribution, targeting, and internalization of the sst4 somatostatin receptor in rat brain. J. Neurosci. 20 (2000) 3785-3797
77. Schulz S., Handel M., Schreff M., Schmidt H., and Hollt V. Localization of five somatostatin receptors in the rat central nervous system using subtype-specific antibodies. J. Physiol. Paris 94 (2000) 259-264
78. Selmer I.S., Schindler M., Humphrey P.P., and Emson P.C. Immunohistochemical localization of the somatostatin sst(4) receptor in rat brain. Neuroscience 98 (2000) 523-533
79. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., and Roses A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 1977-1981
80. Stroh T., Kreienkamp H.J., and Beaudet A. Immunohistochemical distribution of the somatostatin receptor subtype 5 in the adult rat brain: predominant expression in the basal forebrain. J. Comp. Neurol. 412 (1999) 69-82
81. Stroh T., Sarret P., Tannenbaum G.S., and Beaudet A. Immunohistochemical distribution and subcellular localization of the somatostatin receptor subtype 1 (sst1) in the rat hypothalamus. Neurochem. Res. 31 (2006) 247-257
82. Suresh S., Yan Z., Patel R.C., Patel Y.C., and Patel S.C. Cellular cholesterol storage in the Niemann-Pick disease type C mouse is associated with increased expression and defective processing of apolipoprotein D. J. Neurochem. 70 (1998) 242-251
83. Terrisse L., Seguin D., Bertrand P., Poirier J., Milne R., and Rassart E. Modulation of apolipoprotein D and apolipoprotein E expression in rat hippocampus after entorhinal cortex lesion. Brain Res. Mol. Brain Res. 70 (1999) 26-35
84. Terrisse L., Poirier J., Bertrand P., Merched A., Visvikis S., Siest G., Milne R., and Rassart E. Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer's patients. J. Neurochem. 71 (1998) 1643-1650
85. Thomas E.A., and Yao J.K. Clozapine specifically alters the arachidonic acid pathway in mice lacking apolipoprotein D. Schizophr. Res. 89 (2007) 147-153
86. Thomas E.A., George R.C., and Sutcliffe J.G. Apolipoprotein D modulates arachidonic acid signaling in cultured cells: implications for psychiatric disorders. Prostaglandins Leukot. Essent. Fatty Acids 69 (2003) 421-427
87. Thomas E.A., Copolov D.L., and Sutcliffe J.G. From pharmacotherapy to pathophysiology: emerging mechanisms of apolipoprotein D in psychiatric disorders. Curr. Mol. Med. 3 (2003) 408-418
88. Thomas E.A., Dean B., Pavey G., and Sutcliffe J.G. Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 4066-4071
89. Thomas E., and Kass K.E. Apolipoprotein D knock-out mice exhibit hypersensitivity to 3-nitropropionic acid-induced striatal lesions. J. Neurochem. 96 (2006) 79
90. Tran V.T., Uhl G.R., Perry D.C., Manning D.C., Vale W.W., Perrin M.H., Rivier J.E., Martin J.B., and Snyder S.H. Autoradiographic localization of somatostatin receptors in rat brain. Eur. J. Pharmacol. 101 (1984) 307-309
91. Uhl G.R., Tran V., Snyder S.H., and Martin J.B. Somatostatin receptors: distribution in rat central nervous system and human frontal cortex. J. Comp. Neurol. 240 (1985) 288-304
92. Vecsei L., Csala B., Widerlov E., Ekman R., Czopf J., and Palffy G. Lumbar cerebrospinal fluid concentrations of somatostatin and neuropeptide Y in multiple sclerosis. Brain Res. Bull. 25 (1990) 411-413
93. Yagami T., Ueda K., Asakura K., Sakaeda T., Kuroda T., Hata S., Kambayashi Y., and Fujimoto M. Effects of S-2474, a novel nonsteroidal anti-inflammatory drug, on amyloid beta protein-induced neuronal cell death. Br. J. Pharmacol. 134 (2001) 673-681
94. Yoshida K., Cleaveland E.S., Nagle J.W., French S., Yaswen L., Ohshima T., Brady R.O., Pentchev P.G., and Kulkarni A.B. Molecular cloning of the mouse apolipoprotein D gene and its upregulated expression in Niemann-Pick disease type C mouse model. DNA Cell Biol. 15 (1996) 873-882
95. Zhang X., Li D., Duan S., Duan Y., Chen Q., Li X., Liu Z., Feng G., and He L. Analysis of the association between Apolipoprotein D and schizophrenia. Neuropsychobiology 54 (2006) 40-44